Efficacy and safety of radiotherapy combined with anti‐angiogenic therapy and immune checkpoint inhibitors in MSS/pMMR metastatic colorectal cancer

Efficacy and safety of radiotherapy combined with anti‐angiogenic therapy and immune checkpoint inhibitors in MSS/pMMR metastatic colorectal cancer

Abstract Purpose Several studies have demonstrated the effectiveness of anti‐angiogenic drugs in combination with immune checkpoint inhibitors (ICIs) in patients with microsatellite stable (MSS) or mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC). However, whether combination ra...

Full description

Bibliographic Details
Main Authors:	Menglan Zhai, Zixuan Zhang, Haihong Wang, Jinghua Ren, Sheng Zhang, Mingjie Li, Lichao Liu, Lisha Li, Lan Zhang, Xin Li, Tao Zhang, Zhenyu Lin
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	Cancer Medicine
Subjects:	immunotherapy metastatic colorectal cancer microsatellite stable radiotherapy targeted therapy
Online Access:	https://doi.org/10.1002/cam4.6820

Similar Items

Identification of beneficial populations for targeted-immunotherapy combinations: tailoring later-line care for patients with pMMR/MSS metastatic colorectal cancer
by: Dan Li, et al.
Published: (2024-10-01)

Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer
by: Yuwei Ding, et al.
Published: (2023-11-01)

Combination of pembrolizumab and lenvatinib in second-line therapy for MSS/pMMR advanced endometrial cancer: literature review and a case report
by: A. D. Darenskaya, et al.
Published: (2024-01-01)

PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report
by: Jiabao Yang, et al.
Published: (2023-04-01)

Efficacy of immune checkpoint inhibitors combined with bevacizumab in MSS/pMMR advanced colorectal cancer after first-line treatment failure
by: Xiaoqian Chen, et al.
Published: (2024-08-01)

Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer
by: Naoya Sakamoto, et al.
Published: (2024-02-01)

Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer
by: Ting Wang, et al.
Published: (2023-03-01)

A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX
by: Zhu J, et al.
Published: (2023-02-01)

Later lines in pMMR/MSS metastatic colorectal cancer: News opportunities with immunotherapy and local treatments
by: Alfredo Colombo, et al.
Published: (2024-01-01)

PD‐1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer
by: Fengyun Pei, et al.
Published: (2024-06-01)

Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States
by: Sneha S. Kelkar, et al.
Published: (2022-08-01)

Age-related outcomes in MSI/dMMR gastrointestinal cancers treated by immune checkpoint inhibitors and toxicity’s impact on efficacy: an immunoMSI cohort study
by: L. Mailly-Giacchetti, et al.
Published: (2024-06-01)

Squamous cell carcinoma of ascending colon with pMMR/MSS showed a partial response to PD-1 blockade combined with chemotherapy: A case report
by: Yan Liu, et al.
Published: (2023-03-01)

Case report: Durable response from tegafur/gimeracil/oteracil (S-1) combined with fruquintinib and sintilimab as a third-line treatment for MSS metastatic colorectal cancer with a BRAF V600E mutation
by: Chunxia He, et al.
Published: (2024-12-01)

High and low dose radiotherapy combined with ICIs for MSS colorectal cancer patients with liver metastases: a phase I study (HaRyPOT)
by: Yuxuan Ding, et al.
Published: (2025-02-01)

Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)Research in context
by: Wensi Zhao, et al.
Published: (2023-12-01)

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyResearch in context
by: Marwan Fakih, et al.
Published: (2023-04-01)

SPP1+ macrophages and FAP+ fibroblasts promote the progression of pMMR gastric cancer
by: Zhixiong Su, et al.
Published: (2024-10-01)

Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
by: Yanrong Wang, et al.
Published: (2025-03-01)

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trialResearch in context
by: Xuefeng Fang, et al.
Published: (2023-08-01)

Development of a whole-slide-level segmentation-based dMMR/pMMR deep learning detector for colorectal cancer
by: Zhou Tong, et al.
Published: (2023-12-01)

B7H4 Expression Is More Frequent in MSS Status Colorectal Cancer and Is Negatively Associated with Tumour Infiltrating Lymphocytes
by: Miriam Dawidowicz, et al.
Published: (2023-03-01)

Identification of hub genes and potential molecular mechanisms in MSS/MSI classifier primary colorectal cancer based on multiple datasets
by: Xia Qiao, et al.
Published: (2024-07-01)

Progress of Biomarkers to Predict Response to Immune Checkpoint Inhibitors in Microsatellite Stability Colorectal Cancer
by: WANG Zhiqiang, et al.
Published: (2023-02-01)

Neoadjuvant immunotherapy for DNA mismatch repair proficient/microsatellite stable non-metastatic rectal cancer: a systematic review and meta-analysis
by: Huan Zhang, et al.
Published: (2025-01-01)

Prognostic value of Lynch syndrome, BRAFV600E, and RAS mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts
by: Koen Zwart, et al.
Published: (2023-08-01)

GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T CellsSummary
by: Yannick S. Rakké, et al.
Published: (2023-01-01)

Efficacy and Safety of Fruquintinib Combined with Sintilimab in Treatment of Advanced Microsatellite Stable Colorectal Cancer
by: LI Shan, et al.
Published: (2023-12-01)

Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer
by: Chao Liu, et al.
Published: (2022-11-01)

Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
by: Javier Ros, et al.
Published: (2023-02-01)

Does PD-1 blockade play a decisive role in the pathological complete remission of unresectable MSS, BRAF V600E-mutated metastatic colorectal cancer: A case report
by: Li Tan, et al.
Published: (2023-01-01)

Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer
by: Wen-Xuan Fan, et al.
Published: (2024-08-01)

Review of the application of dMMR and microsatellite instability in the diagnosis and treatment of endometrial cancer
by: Guangjie Liao, et al.
Published: (2021-01-01)

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer
by: Qingli Li, et al.
Published: (2022-03-01)

High Frequency of Microsatellite Instability among Non-Metastatic Gastric Cancer
by: Khadijeh Fanaei, et al.
Published: (2022-10-01)

Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
by: Anne Hansen Ree, et al.
Published: (2024-12-01)

Microsatellite Instability and MMR Genes Abnormalities in Canine Mammary Gland Tumors
by: Faiz Muhammad Khand, et al.
Published: (2020-02-01)

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China
by: Miaomiao Gou, et al.
Published: (2022-07-01)

Expression of MMR in 515 cases of endometrioid adenocarcinoma and its correlation with clinicopathological features
by: WU Quan, GUO Jingwei, LEI Yuxin, HU Xiaoru, WANG Zhe
Published: (2022-12-01)

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
by: Xuan Zhang, et al.
Published: (2022-03-01)